CDTX Rasio cepet Cidara Therapeutics Inc

Cidara Therapeutics (CDTX) develops advanced antiviral agents. The price action of the securities on GURU.Markets reflects the impact of geopolitical risks and constraints on external financing, with the metric standing at 4.79. Production facilities consistently output products, implementing new formulas without interruption. Successful tests will enable the company to exercise pricing power over therapy costs due to the uniqueness of its developments.

CDTX: Rasio jangkoan perantara Cidara 04.07.2022 - 17.01.2026

Ringkesan rincian data analitis Cidara Therapeutics Inc (CDTX)

- nilai pasar lan prakiraan target analis:

Bagan rega Cidara|CDTX - Target konsensus

- data kapitalisasi pasar:

Kapitalisasi pasar Cidara Therapeutics Corp|CDTX - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Akuntansi saben Saham Cidara|CDTX - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi marang Aset Bersih cidara.com|CDTX - Aset Agregat Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Cidara Therapeutics|CDTX - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Cidara Therapeutics Corp|CDTX - Kewajiban utang agregat|Utang marang nilai buku Cidara Therapeutics Corp|CDTX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Cidara|Rasio cepet cidara.com

- informasi bathi lan kelipatan valuasi:

CDTX - Penghasilan resik

Ringkesan analitik perusahaan:Cidara Therapeutics, CDTX

Barang unggulan Cidara Therapeutics Corp

Quick liquidity measures a company's ability to instantaneously settle its obligations using only cash and accounts receivable, excluding low-liquidity inventory. Analyzing the strict solvency level of Cidara Therapeutics (CDTX) reveals how the availability of liquid capital supports the transformation of its antiviral drug portfolio and R&D partnerships, confirming the business's financial stability while minimizing operational risks.

Analisis pesaing